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Translational Investigation

Hair cortisol as a novel biomarker of HPA suppression by
inhaled corticosteroids in children
Laura Smy1,2, Kaitlyn Shaw3–5, Anne Smith3–5, Evan Russell6, Stan Van Uum6, Michael Rieder6, Bruce Carleton3–5 and
Gideon Koren1,2,6
Background: Asthma is the most common chronic condition in childhood, and the recommended pharmacotherapy for
long-term control includes the use of inhaled corticosteroids
(ICS). ICS were designed to act at the site of inflammation in the
lung, thus decreasing systemic absorption and reducing the
risk of adverse effects associated with corticosteroid use (e.g.,
HPA suppression and its consequent effects). Available data
show that measurement of hair cortisol successfully reflects
endogenous cortisol levels. We sought to examine whether
hair cortisol measurements can be used to identify HPA suppression surrounding ICS therapy in children with asthma.
Methods: Hair samples were collected from the vertex posterior region of the head of 18 asthmatic children. We compared their hair cortisol concentration during ICS use with the
concentration prior to ICS use.
Results: During ICS therapy, median hair cortisol levels were
twofold lower compared with the period of no ICS use (median
89.8 ng/g vs. 198.2 ng/g, P = 0.0015).
Conclusion: Hair cortisol is an effective biomarker of the
HPA suppression associated with ICS therapy and can be a
sensitive tool for determining systemic effects of ICS use and
monitoring adherence. Future research is needed to characterize the effect of untreated asthma on hair cortisol concentrations, if any.

A

sthma is the most common chronic disease in childhood, affecting ~10% of children between the ages of 2
and 7 y (1). Inhaled corticosteroids (ICS) are first-line anti-
inflammatory drugs used in the long-term treatment of asthma
(2). Currently, there are five different generic ICS available in
Canada: budesonide, fluticasone propionate, beclomethasone
dipropionate, mometasone furoate, and ciclesonide. These
agents are designed to achieve therapeutic levels through
topical application at the receptor site in the lung, thereby
providing a lower level of systemic absorption and decreased
risk of adverse effects compared with systemic corticosteroid

treatments (3). However, in children, there are still concerns
that chronic use of these agents may lead to adverse effects
such as stunted growth (4), or HPA suppression (5), which
is the focus of our research. Previous studies have found an
association between ICS use in children and decreased salivary
cortisol (6), as well as incidents of adrenal crisis, a potentially
life-threatening condition (7).
Presently, clinical laboratory measurements of systemic
cortisol levels use blood, saliva, or urine samples, all of which
reflect short-term periods of hours to days. Due to the circadian
variation in cortisol levels, the use of these matrices requires
multiple measurements to truly understand cortisol changes
over time (8). Over the last decade, hair cortisol measurement
has emerged as a promising biomarker of long-term changes
in the HPA (9). Studies have shown that hair concentrations
of cortisol parallel plasma levels. For example, in patients with
Cushing syndrome, resection of the adenoma resulted in a
steep decrease in plasma and urine cortisol levels, paralleled
by a similar temporal decline in hair concentrations (10). Since
hair grows at an average rate of 1 cm per month (cm/mo) at the
vertex posterior region of the head (11), a segmental analysis
of hair is able to reveal changes in cortisol levels over time (8).
The aim of our pilot study was to examine whether hair cortisol can detect HPA suppression, specifically decreased cortisol
release, after initiation of ICS use in children with asthma.
RESULTS
Hair samples from 18 children with asthma were analyzed. The
patient demographics and description of ICS and concomitant
steroid use are listed in Table 1. Further details for each individual patient regarding the type and duration of ICS use and
the associated relative change in hair cortisol concentration are
depicted in Figure 1. The median hair cortisol concentration
was twofold lower during periods of ICS exposure compared
with the control period with no exposure to ICS (89.8 ng/g
(IQR, 24.5–256.5) vs. 198.2 ng/g (IQR, 56.2–798.0); P = 0.0015,
Figure 2).
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Table 1. Patient demographics (n = 18)
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Gender, F (M)

15 (3)

Duration of ICS use (mo), median (range)

5.1 (2.3–20.7)

ICS dosea, number of patients
Low

7

Low/moderate

9

Moderate

2

Change in hair cortisol (%)

Age (y), median (range)

Duration of ICS use (mo)

Characteristic
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ICS frequency of usea, number of patients
Intermittent

1

Intermittent/continuous

8

Continuous

9

Switched from one type of ICS to another during
therapy, number of patients

0

9

0
1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17

18

Types of ICS used, number of patientsb
Ciclesonide
Fluticasone propionate
Beclomethasone
Combination, total (mometasone/fluticasone
propionate)

14
9
1
3 (2/1)
Patient

Use of other corticosteroids during the periods assessed
by hair cortisol results, number of patients
Systemic —total
c

7

Prior to starting ICS

2

After starting ICS

6

>1 course

1

Intranasal

5

ICS, inhaled corticosteroids.
a
See Methods for definitions. bSome patients used more than one type of ICS, which
was captured by the hair analysis. Therefore, the total of all patients by ICS type is
greater than the sample size of 18. cCount restricted to patients who received systemic
corticosteroids during the periods captured by the hair segments included in the
statistical analysis.

DISCUSSION
Despite the perception that there is low systemic bioavailability of ICS compared with oral or intravenous steroids, there
is evidence of unexpected ICS-induced adverse effects in children such as height deficits that persist into adulthood with
long-term budesonide use (12). Moreover, children have been
repeatedly documented as experiencing adrenal suppression,
insufficiency, or crisis while receiving ICS (6,7,13). These
adverse effects depend on the dose, duration of therapy, and
age at the initiation of therapy. Moreover, it is likely that the
different ICS pharmacokinetic characteristics are a determinant of adverse effects given the impact of pharmacokinetic
properties on systemic activity (4).
The measurements of hair cortisol have been shown to be
a sensitive biomarker of Cushing syndrome (10,14), as well
as stress associated with chronic pain, myocardial infarction,
congestive heat failure, and numerous other conditions (8).
Changes in hair cortisol can be detected in hair within 2 mo of
the corresponding changes in plasma cortisol. In the pediatric
Copyright © 2015 International Pediatric Research Foundation, Inc.
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Figure 1. Individual patient inhaled corticosteroids (ICS) therapy duration and associated percent change in hair cortisol before ICS therapy
compared to during ICS Therapy. Stacked bar graph displays the data
for each of the 18 individual patients along the x-axis from left to right.
Each patient’s percent change in hair cortisol is indicated using the right
y-axis and the white bar with the majority of children showing a negative
change in hair cortisol. The duration of ICS use in months is indicated
along the left y-axis with the bars extending in the positive direction. Each
bar is coded to indicate the specific ICS used by the patient as follows:
ciclesonide (black bar), fluticasone propionate (gray bar), beclomethasone dipropionate (left-downward hatched bar), mometasone furoate
combination (right-downward hatched bar), and fluticasone propionate
combination (horizontal hatched bar). Nine patients switched the type of
ICS used, as shown by the change in color or pattern of the bar, and the
hair segments that were analyzed for cortisol captured this switch. The
bars for duration of ICS use also illustrate the length of the hair that was
segmented for cortisol analysis during ICS therapy based on the average
growth rate of 1 cm/mo, but it is an overestimation to a varying degree
for each patient due to the exclusion of the hair segment when ICS was
initiated.

context, this is a noninvasive method that makes it ethically
more acceptable than drawing a blood sample by venipuncture. The ability of hair cortisol to serve as a sensitive biomarker
of systemic suppression of the HPA may offer clinicians and
researchers a time-sensitive tool to monitor the suppression
of cortisol secretion in children with asthma who receive ICS,
as well as in patients with other causes of decreased cortisol
release.
Preliminary peer review reports suggested that ciclesonide
may be associated with fewer adverse effects on growth in children (15), and adrenal suppression in adults (16,17). Fewer
observed adverse effects are believed to occur because ciclesonide is administered as a prodrug and activated by esterases in
the lung, as well as its low oral bioavailability, rapid elimination,
and high plasma protein binding (16). One article describing
Volume 78 | Number 1 | July 2015      Pediatric Research 
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Figure 2. Comparison of median average monthly hair cortisol concentration before and during ICS therapy. Tukey boxplot comparison of the
patients’ median average monthly hair cortisol results for a maximum
6-mo period prior to ICS therapy and minimum 2-mo period during ICS
therapy (n = 18). *P = 0.0015.

four case studies with normalized adrenal cortisol release after
switching from fluticasone to ciclesonide even suggests that
ciclesonide use should be considered to potentially reverse adrenal suppression secondary to the use of other ICS (18). With
14 out of 18 children in our study using ciclesonide, 6 of whom
have never used any other ICS, our findings contradict this sentiment and instead suggest that HPA suppression does occur
with the use of ciclesonide.
The use of intranasal steroids and systemic steroids by some
of our patients is a possible confounder. However, the use of
intranasal corticosteroids has not been shown to decrease
endogenous cortisol levels more than the use of ICS alone
(6); and short-course systemic corticosteroid therapy for the
treatment of asthma, as recommended by asthma treatment
guidelines (19), was not associated with long-term suppression of adrenal function (20,21). Furthermore, a hair cortisol
analysis has the advantage of representing an overall picture of
adrenal cortisol production and function of the HPA, rather
than indicating acute or short-term fluctuations. Additional
confounding may be present with the analysis of older hair
segments. While the majority of studies have not found an
association with the frequency of hair washing, some have
reported declining hair cortisol in older hair segments (22).
This may be in part due to repeated shampooing as found by
Hamel et al. (23). Should this confounding be present in our
46 Pediatric Research      Volume 78 | Number 1 | July 2015

study, our results would underestimate any decrease or overestimate any increase observed when comparing the hair cortisol levels prior to ICS use with those during ICS use.
The results of a recent study analyzing hair cortisol in children with asthma receiving ICS were similar to our findings
with reported cortisol levels twofold lower than those in children without asthma (24). However, it was unknown whether
the decrease in cortisol was due to the inflammatory condition
itself or due to the effect of ICS. Our study addresses this issue
by having the same children as the control group, which makes
it less likely that the changes are due to the disease itself. As our
study is a pilot investigation, it lacks the statistical power to discern dose- or product-dependent differences. Regardless, our
results clearly show that hair cortisol is an effective biomarker
of HPA suppression by ICS with respect to cortisol production.
In summary, hair cortisol is an effective biomarker of the
HPA suppression associated with ICS therapy. Since hair
grows 1 cm/mo on average and although it takes new hair several days to surface, hair cortisol determination can serve as
a sensitive tool for detecting adrenal suppression due to ICS
therapy and for monitoring adherence, and potentially can be
used for assessing the effects of changes in ICS type or dose.
Additionally, it may be used in the investigation of other conditions associated with reduced cortisol release. Larger studies
are needed to confirm and extend these findings. Furthermore,
it will be important to compare hair cortisol of patients with
asthma treated with ICS with that of disease-matched controls,
as well as healthy controls, to fully discern the effect of the disease and the drug on hair cortisol levels.
METHODS

We identified children with asthma who had a history of at least 2 mo
of ICS use preceded by a period of up to 6 mo without ICS, which
could be captured by a hair sample. ICS use was categorized as intermittent if the ICS were prescribed for cold symptoms or seasonal use
only, or continuous if prescribed for daily use. We did not exclude
those who were exposed to short courses of systemic corticosteroids
or intranasal corticosteroids. We categorized each patient’s dose
based on beclomethasone–hydrofluoroalkane equivalents as defined
by Lougheed et al. (19). No patient in the study group was receiving
high-dose ICS.
Full-length hair (40 or more strands) was collected noninvasively
by cutting with scissors from the vertex posterior region of the head
and sectioned into 2-cm segments to capture the periods of exposure
or no exposure to ICS, based on an average hair growth rate of 1 cm/
mo. Hair cortisol was extracted and quantified by a validated enzymelinked immunosorbent assay method routinely used in our laboratory
with a reported intraday and interday coefficient of variation of 3.8
and 8%, respectively (25). A high correlation between the results of
the enzyme-linked immunosorbent assay and those of liquid chromatography–mass spectrometry has been demonstrated (r2 > 0.9) (26),
proving the validity of our cortisol measurement method.
For each participant, the average monthly hair cortisol for a maximum 6-mo period prior to ICS use and minimum 2-mo period during ICS use was determined. The hair segment corresponding to the
period when ICS use was initiated was not included in the analysis
to avoid variability in cortisol hair levels during the period of ICS
buildup. The exclusion also aimed to reduce the influence of systemic
corticosteroid exposure as this was frequently given at the time of
starting ICS therapy. Because the average hair cortisol concentrations
were not normally distributed, the median of the average monthly
hair cortisol concentrations prior to and during the use of ICS was
Copyright © 2015 International Pediatric Research Foundation, Inc.
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compared using the Wilcoxon matched-pairs signed-rank test with a
two-tailed P-value. The statistical analysis was performed using Prism
software, version 5.0c (Graphpad Software, La Jolla, CA).
The research ethics boards of the University of British Columbia,
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specified by the respective research ethics boards.
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